In mouse brain tumour xenografts, onartuzumab and MET404 antibody treatment achieved partial inhibition of MET phosphorylation and tumour progression; the combination of these two approaches, however, maximally inhibited GBM progression as well as in vivo MET signalling and prolonged the overall survival of the experimental mice to more than 60 days (MST 56–59 days, Fig. 7e–g). Here, MET is linked to glioblastoma.